Toxicity Concerns Cast Uncertainty on Phase 3 Results of AstraZeneca and Daiichi Cancer Drug
A targeted cancer therapy developed by AstraZeneca and Daiichi Sankyo has shown promising results in a Phase 3 study for advanced non-small cell lung cancer (NSCLC). The drug, called datopotamab deruxtecan, demonstrated a statistically significant improvement in progression-free survival compared to chemotherapy. However, the companies also disclosed that an unspecified number of patient deaths occurred […]